FOLH1 and neoplasm: As in the PSMA cohort, the RSClin tool provided more prognostic information than either RS result alone or clinical-pathological characteristics alone using likelihood ratio tests in patients who received endocrine therapy alone with linear effects for RS result, tumor size, and age (RSClin tool v PC [P = .027] and RSClin tool v RS result [P = .004]).